Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste.
RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...
The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...
NMU-Symphony™ is the next generation of the Nutcracker ® Manufacturing Unit, optimized for RNA-based individualized manufacturing of therapeutics The company has successfully completed manufacturing ...
SEOUL, Korea--(BUSINESS WIRE)--GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a ...
The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is similarly ...
LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...
Ascidian Therapeutics (“Ascidian”), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the ...
mRNA Synthesis and Manufacturing Market to Witness a Leap by Leaching CAGR of ~6% By The End Of 2030
Global mRNA Synthesis and Manufacturing Market OverviewThe global mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate of approximately 6% during the forecast ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results